Fiduciary Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.41M | Sell |
7,013
-26
| -0.4% | -$26.6K | 0.66% | 40 |
|
|
2026
Q1 | $6.47M | Sell |
7,039
-84
| -1% | -$85.2K | 0.55% | 49 |
|
|
2025
Q4 | $7.65M | Sell |
7,123
-225
| -3% | -$215K | 0.64% | 41 |
|
|
2025
Q3 | $5.61M | Buy |
7,348
+23
| +0.3% | +$17.1K | 0.49% | 54 |
|
|
2025
Q2 | $5.71M | Sell |
7,325
-45
| -0.6% | -$35K | 0.54% | 50 |
|
|
2025
Q1 | $6.09M | Sell |
7,370
-3
| -0% | -$2.5K | 0.61% | 47 |
|
|
2024
Q4 | $5.69M | Buy |
7,373
+151
| +2% | +$125K | 0.57% | 49 |
|
|
2024
Q3 | $6.4M | Buy |
7,222
+70
| +1% | +$62.9K | 0.65% | 43 |
|
|
2024
Q2 | $6.48M | Sell |
7,152
-164
| -2% | -$131K | 0.7% | 38 |
|
|
2024
Q1 | $5.69M | Buy |
7,316
+176
| +2% | +$125K | 0.62% | 48 |
|
|
2023
Q4 | $4.16M | Sell |
7,140
-150
| -2% | -$87.6K | 0.49% | 55 |
|
|
2023
Q3 | $3.92M | Sell |
7,290
-300
| -4% | -$155K | 0.5% | 53 |
|
|
2023
Q2 | $3.56M | Sell |
7,590
-36
| -0.5% | -$15.1K | 0.44% | 59 |
|
|
2023
Q1 | $2.62M | Sell |
7,626
-50
| -0.7% | -$16.9K | 0.34% | 74 |
|
|
2022
Q4 | $2.81M | Sell |
7,676
-286
| -4% | -$101K | 0.37% | 68 |
|
|
2022
Q3 | $2.94M | Buy |
7,962
+272
| +4% | +$86.2K | 0.38% | 65 |
|
|
2022
Q2 | $2.32M | Buy |
7,690
+1
| +0% | +$300 | 0.29% | 75 |
|
|
2022
Q1 | $2.2M | Buy |
7,689
+13
| +0.2% | +$3.35K | 0.29% | 74 |
|
|
2021
Q4 | $2.12M | Sell |
7,676
-150
| -2% | -$38K | 0.24% | 80 |
|
|
2021
Q3 | $1.94M | Sell |
7,826
-275
| -3% | -$67.9K | 0.22% | 79 |
|
|
2021
Q2 | $2.13M | Sell |
8,101
-75
| -0.9% | -$15.1K | 0.25% | 75 |
|
|
2021
Q1 | $1.49M | Sell |
8,176
-101
| -1% | -$19.8K | 0.18% | 94 |
|
|
2020
Q4 | $1.68M | Sell |
8,277
-200
| -2% | -$29.9K | 0.22% | 82 |
|
|
2020
Q3 | $1.25M | Hold |
8,477
| – | – | 0.19% | 88 |
|
|
2020
Q2 | $1.39M | Buy |
8,477
+100
| +1% | +$15.3K | 0.23% | 77 |
|
|
2020
Q1 | $1.16M | Sell |
8,377
-104
| -1% | -$14.3K | 0.23% | 75 |
|
|
2019
Q4 | $1.11M | Sell |
8,481
-145
| -2% | -$16.8K | 0.18% | 84 |
|
|
2019
Q3 | $965K | Sell |
8,626
-1,262
| -13% | -$141K | 0.17% | 88 |
|
|
2019
Q2 | $1.09M | Sell |
9,888
-423
| -4% | -$49.8K | 0.2% | 85 |
|
|
2019
Q1 | $1.34M | Sell |
10,311
-45
| -0.4% | -$5.47K | 0.25% | 79 |
|
|
2018
Q4 | $1.2M | Sell |
10,356
-445
| -4% | -$49.7K | 0.25% | 79 |
|
|
2018
Q3 | $1.16M | Buy |
10,801
+130
| +1% | +$13K | 0.23% | 85 |
|
|
2018
Q2 | $911K | Sell |
10,671
-1,065
| -9% | -$87.5K | 0.19% | 87 |
|
|
2018
Q1 | $908K | Sell |
11,736
-353
| -3% | -$28.4K | 0.2% | 90 |
|
|
2017
Q4 | $1.02M | Sell |
12,089
-342
| -3% | -$29.1K | 0.22% | 89 |
|
|
2017
Q3 | $1.06M | Sell |
12,431
-1,026
| -8% | -$84.2K | 0.24% | 88 |
|
|
2017
Q2 | $1.11M | Sell |
13,457
-778
| -5% | -$63.5K | 0.26% | 86 |
|
|
2017
Q1 | $1.2M | Sell |
14,235
-607
| -4% | -$48.6K | 0.28% | 83 |
|
|
2016
Q4 | $1.09M | Sell |
14,842
-2,337
| -14% | -$174K | 0.28% | 82 |
|
|
2016
Q3 | $1.38M | Sell |
17,179
-300
| -2% | -$24K | 0.37% | 72 |
|
|
2016
Q2 | $1.38M | Sell |
17,479
-415
| -2% | -$31.2K | 0.38% | 68 |
|
|
2016
Q1 | $1.29M | Sell |
17,894
-65
| -0.4% | -$4.92K | 0.37% | 69 |
|
|
2015
Q4 | $1.51M | Buy |
17,959
+1,430
| +9% | +$119K | 0.45% | 64 |
|
|
2015
Q3 | $1.38M | Sell |
16,529
-550
| -3% | -$46.4K | 0.46% | 72 |
|
|
2015
Q2 | $1.43M | Buy |
+17,079
| New | +$1.3M | 0.45% | 75 |
|
Other funds holding LLY
Fiduciary Group's LLY Position: Q2 2026 in Review
Fiduciary Group reduced its Eli Lilly (LLY) stake by 0.37% in Q2 2026, selling an estimated $26.6K and leaving 7,013 shares worth $8.41M. The position accounts for 0.66% of the portfolio, ranked #40.
Fiduciary Group first reported a position in LLY in Q2 2015 and has held it in 45 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Fiduciary Group held 7,013 shares of Eli Lilly worth $8.41M as of Q2 2026.
- Fiduciary Group sold 26 Eli Lilly shares in Q2 2026, an estimated $26.6K.
- Eli Lilly made up 0.66% of Fiduciary Group's portfolio in Q2 2026, its #40 holding.
- Fiduciary Group first reported a position in Eli Lilly in Q2 2015 and has held it in 45 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Fiduciary Group's 13F filing for Q2 2026, filed 10 Aug 2026.